November generally makes us think of changing seasons and time with loved ones.  How fitting than that November is also National Alzheimer’s Month, a time for us to celebrate and pay tribute to those in our lives effected by Alzheimer’s disease and dementia.

Alzheimer’s disease is a tragic neurological condition that affects many of our family members, friends, parents and grandparents. An estimated five million Americans are living with Alzheimer’s disease. For every individual with Alzheimer’s, an entire community works to support them in their daily lives.

Alzheimer’s disease is marked by loss of memory, speech, judgment, sense of direction and other brain functions. While currently no cure exists, three risk factors play an important role in your susceptibility.

Read More

Navigenics has a strong showing on Health Spottr’s Future Health 100 list. Health Spottr is a new media publishing company devoted to covering the latest in health care innovation and the top players in health care.  Among its new list of 100 influential health care providers, investors, innovators and executives are Navigenics leaders Dr. Jonathan “Jack” Lord and Dr. David Agus.

Dr. Jack Lord, CEO of Navigenics, is featured at number 19 for his commitment to quality improvement in health care. Dr. Lord discusses the importance of Navigenics’ genetic testing services in the future of health care. “These are all progressions on the same basic track of getting people to a place of sovereignty over their healthcare—putting them on the same level as their doctors in the decision-making. Navigenics represents the next step. We provide people with a science-based view of their future risks, then give them resources to understand how they might impact those risks.”

Read More

There has never been a better time to take control of your health.

Navigenics has reduced the cost of our comprehensive genetic testing services to $999.

Our Health Compass test identifies your genetic predisposition for a wide variety of common conditions such as colon cancer, breast cancer, Alzheimer’s disease and type 2 diabetes, among others.

Not only do you get results, you get a plan of action and guidance to take the next steps.  Our board-certified Genetic Counselors are available to help you understand your results and how you can work with your doctor to minimize your individual risks.

Read More

Navigenics is pleased to announce the appointment of a new company leader. Here are some details, as described in a news release:

Navigenics, a leading personal genomics testing company, announced today that Jonathan “Jack” T. Lord, M.D., has been appointed by the Board of Directors to serve as President and Chief Executive Officer of the firm.

Dr. Lord brings to Navigenics a history and passion for combining robust medical science with technological innovation to improve consumers’ health and access to quality care. Dr. Lord comes to Navigenics from Louisville, Kentucky-based Humana, Inc., where as Chief Innovation Officer he was responsible for designing new products and services to enable people to navigate the healthcare system and support their health needs.  Before Humana, Dr. Lord was president of Health Dialog in Boston, where he helped pioneer e-enabled health care. He has also served as chief operating officer of the American Hospital Association in Washington, D.C.  Previously, Dr. Lord was executive vice president of Anne Arundel Medical Center in Annapolis, MD, and executive vice president of Sun Health in Charlotte, NC.

“I am excited about the prospects of leading a company that will transform healthcare. Navigenics’ leadership in science, its exceptionally committed and leading edge investors, and strong management team make this the most exciting opportunity of my career,” said Dr. Lord.  “Passion for advancing personalized medicine defines Navigenics.  I am very honored to have the privilege to lead this company as we transform healthcare for the 21st century– an era of healthcare we hope will be marked by a focus on prediction and prevention.”

Read More